181 related articles for article (PubMed ID: 12223520)
1. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions.
Taylor L; Bachler M; Duncan I; Keen S; Fallon R; Mair C; McDonald TT; Schwarz H
J Leukoc Biol; 2002 Sep; 72(3):522-9. PubMed ID: 12223520
[TBL] [Abstract][Full Text] [Related]
2. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein.
Higgins LM; McDonald SA; Whittle N; Crockett N; Shields JG; MacDonald TT
J Immunol; 1999 Jan; 162(1):486-93. PubMed ID: 9886424
[TBL] [Abstract][Full Text] [Related]
3. Identification of rat OX40 ligand by molecular cloning.
Akiba H; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 1998 Oct; 251(1):131-6. PubMed ID: 9790919
[TBL] [Abstract][Full Text] [Related]
4. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
6. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.
Calderhead DM; Buhlmann JE; van den Eertwegh AJ; Claassen E; Noelle RJ; Fell HP
J Immunol; 1993 Nov; 151(10):5261-71. PubMed ID: 8228223
[TBL] [Abstract][Full Text] [Related]
7. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.
al-Shamkhani A; Birkeland ML; Puklavec M; Brown MH; James W; Barclay AN
Eur J Immunol; 1996 Aug; 26(8):1695-9. PubMed ID: 8765008
[TBL] [Abstract][Full Text] [Related]
8. Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice.
Sato T; Ishii N; Murata K; Kikuchi K; Nakagawa S; Ndhlovu LC; Sugamura K
Eur J Immunol; 2002 Nov; 32(11):3326-35. PubMed ID: 12555678
[TBL] [Abstract][Full Text] [Related]
9. Intracellular signaling of gp34, the OX40 ligand: induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40.
Matsumura Y; Hori T; Kawamata S; Imura A; Uchiyama T
J Immunol; 1999 Sep; 163(6):3007-11. PubMed ID: 10477563
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.
Majeau GR; Meier W; Jimmo B; Kioussis D; Hochman PS
J Immunol; 1994 Mar; 152(6):2753-67. PubMed ID: 7511625
[TBL] [Abstract][Full Text] [Related]
11. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection.
Humphreys IR; Walzl G; Edwards L; Rae A; Hill S; Hussell T
J Exp Med; 2003 Oct; 198(8):1237-42. PubMed ID: 14568982
[TBL] [Abstract][Full Text] [Related]
12. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
13. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
14. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.
Flórido M; Borges M; Yagita H; Appelberg R
J Leukoc Biol; 2004 Nov; 76(5):1039-46. PubMed ID: 15316035
[TBL] [Abstract][Full Text] [Related]
15. OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.
Huddleston CA; Weinberg AD; Parker DC
Eur J Immunol; 2006 May; 36(5):1093-103. PubMed ID: 16541471
[TBL] [Abstract][Full Text] [Related]
16. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
17. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system.
Kunitomi A; Hori T; Imura A; Uchiyama T
J Leukoc Biol; 2000 Jul; 68(1):111-8. PubMed ID: 10914497
[TBL] [Abstract][Full Text] [Related]
19. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
20. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
